Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 22.74 percent. This is a 142.86 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $10.254 million which missed the analyst consensus estimate of $10.946 million by 6.32 percent. This is a 0.41 percent decrease over sales of $10.296 million the same period last year.